Mir-509-5p joins the Mdm2/p53 feedback loop and regulates cancer cell growth

Cell Death and Disease

Volumn 5, Issue 8, 2014, Pages

  Ren, Z J ^a   Nong, X Y ^a   Lv, Y R ^a   Sun, H H ^a   An, P P ^a   Wang, F ^a   Li, X ^a   Liu, M ^a   Tang, H ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3' UNTRANSLATED REGION; ANTISENSE OLIGONUCLEOTIDE; MDM2 PROTEIN, HUMAN; MICRORNA; PROTEIN BINDING; PROTEIN MDM2; PROTEIN P53;

3' UNTRANSLATED REGION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; DNA RESPONSIVE ELEMENT; G1 PHASE CELL CYCLE CHECKPOINT; GENETICS; HELA CELL LINE; HEPG2 CELL LINE; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; PROMOTER REGION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINTS; HELA CELLS; HEP G2 CELLS; HUMANS; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; RESPONSE ELEMENTS; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906878278     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.327     Document Type: Article

References (37)

1. Cech TR, Steitz JA. The noncoding RNA revolution-trashing old rules to forge new ones. Cell 2014; 157: 77-94.
2. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012; 148: 1172-1187.
3. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755-11760.
4. Eades G, Yang M, Yao Y, Zhang Y, Zhou Q. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem 286: 40725-40733.
5. Cho WC, Chow AS, Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer 2009; 45: 2197-2206.
6. Yan Y, Luo YC, Wan HY, Wang J, Zhang PP, Liu M et al. MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelialmesenchymal transition and adhesion in hepatoma cells. Hepatology 57: 667-677.
7. Chen L, Yang Q, Kong WQ, Liu T, Liu M, Li X et al. MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas. IUBMB Life 64: 628-635.
8. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005; 436: 214-220.
9. Kong W, Yang H, He L, Zhao J-j, Coppola D, Dalton WS et al. MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008; 28: 6773-6784.
10. Merkel O, Asslaber D, Pinon J, Egle A, Greil R. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle 2010; 9: 2836-2840.
11. Fernandez-Fernandez MR, Rutherford TJ, Fersht AR. Members of the S100 family bind p53 in two distinct ways. Protein Sci 2008; 17: 1663-1670.
12. Hofmann TG, Möller A, Sirma H, Zentgraf H, Taya Y, Dröge W et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 2001; 4: 1-10.
13. Juan L-J, Shia W-J, Chen M-H, Yang W-M, Seto E, Lin Y-S et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000; 275: 20436-20443.
14. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24: 2899-2908.
15. Dubs-Poterszman MC, Tocque B, Wasylyk B. Mdm2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 1995; 11: 2445-2449.
16. Peng Y, Chen L, Li C, Lu W, Agrawal S, Chen J. Stabilization of the Mdm2 oncoprotein by mutant p53. J Biol Chem 2001; 276: 6874-6878.
17. Wade M, Li YC, Matani AS, Braun SM, Milanesi F, Rodewald LW et al. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells. Oncogene 31: 4789-4797.
18. Bond GL, Hu W, Levine AJ. Mdm2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005; 5: 3-8.
19. Dar AA, Majid S, Rittsteuer C, de Semir D, Bezrookove V, Tong S et al. The role of miR-18b in Mdm2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst 105: 433-442.
20. Chesi M, Bergsagel PL. Epigenetics and microRNAs combine to modulate the Mdm2/p53 axis in myeloma. Cancer Cell 18: 299-300.
21. Xiao J, Lin H, Luo X, Luo X, Wang Z. miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J 30: 5021.
22. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H. Mdm2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther 9: 936-944.
23. Love IM, Shi D, Grossman SR. p53 Ubiquitination and proteasomal degradation. Methods Mol Biol 962: 63-73.
24. Aigner A. MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. J Mol Med (Berl) 89: 445-457.
25. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
26. Hanlon K, Rudin CE, Harries LW. Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL). PLoS One 2009; 4: e7169.
27. Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J et al. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 2009; 26: 27-34.
28. Zanesi N, Pekarsky Y, Trapasso F, Calin G, Croce CM. MicroRNAs in mouse models of lymphoid malignancies. J Nucleic Acids Investig 1: 36-40.
29. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
30. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
31. Waby JS, Chirakkal H, Yu C, Griffiths GJ, Benson RS, Bingle CD et al. Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer 9: 275.
32. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-1134.
33. Ba YH, Li HP. Advances in study of murine double minute 2/p53 passway with breast cancer. Beijing Da Xue Xue Bao 2006; 38: 551-554.
34. Chang C-J, Freeman DJ, Wu H. PTEN regulates Mdm2 expression through the P1 promoter. J Biol Chem 2004; 279: 29841-29848.
35. Héron-Milhavet L, LeRoith D. Insulin-like growth factor I induces Mdm2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 2002; 277: 15600-15606.
36. Xiao J, Lin H, Luo X, Luo X, Wang Z. miR-605 joins p53 network to form a p53: miR-605: Mdm2 positive feedback loop in response to stress. EMBO J 2011; 30: 524-532.
37. Hwang HW, Wentzel EA, Mendell JT 2007A hexanucleotide element directs microRNA nuclear import. Science 315: 97-100.